This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Schreiber raises questions about the potential relationship of aPTT values and coronary events. In the patients randomized to receive unfractionated heparin in the SYNERGY trial, approximately 33% and 44% were "therapeutic" (aPTT, 50-70 seconds) within the first 6 through 12 and 13 through 24 hours of randomization, respectively. We have been evaluating the information available in patients randomized to the unfractionated heparin group who received either no prior antithrombin therapy or who had received unfractionated heparin prior to randomization (n = 2608). This is a "pure" unfractionated heparin group similar to those patients enrolled in the OASIS-2 trial,¹ which studied 5058 patients with a non–ST-segment elevation acute coronary syndrome receiving intravenous unfractionated heparin. In contrast to OASIS-2, we did not find a relationship between aPTT values and recurrent ischemic events, defined as death, (re)infarction, stroke, or recurrent angina requiring coronary revascularization at 7 days. Similarly, after adjusting for other . . . [Full Text of this Article]

Kenneth W. Mahaffey, MD
mahaf002@notes.duke.edu
Duke University Medical Center
Durham, NC

Shaun G. Goodman, MD
St Michael's Hospital
University of Toronto
Toronto, Ontario

RELATED ARTICLES

Low-Molecular-Weight Heparin vs Unfractionated Heparin in Acute Coronary Syndromes
Richard Schreiber
JAMA. 2006;295(20):2353.
EXTRACT | FULL TEXT  

High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin: Outcomes at 6 Months and 1 Year in the SYNERGY Trial
Kenneth W. Mahaffey, Marc Cohen, Jyotsna Garg, Elliott Antman, Neal S. Kleiman, Shaun G. Goodman, Lisa G. Berdan, Craig J. Reist, Anatoly Langer, Harvey D. White, Philip E. Aylward, Jacques J. Col, James J. Ferguson, III, Robert M. Califf, and for the SYNERGY Trial Investigators
JAMA. 2005;294(20):2594-2600.
ABSTRACT | FULL TEXT